Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PRKX | P51817 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | CLPP | Q16740 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035252 | 0.89 | RXRA (0.59) | RXRANR1H2NR1H3CYP1A1CYP1A2 | |
| SCHEMBL1034194 | 0.85 | RXRA (0.42) | RXRANR1H2NR1H3CYP1A2MAOB | |
| SCHEMBL1031597 | 0.82 | RXRA (0.51) | RXRANR1H2NR1H3TDP1 | |
| SCHEMBL1032109 | 0.80 | BACE1 (0.47) | RXRANR1H2NR1H3CYP1A2MAPK14 | |
| SCHEMBL1031634 | 0.78 | RXRA (0.49) | RXRANR1H2NR1H3CYP1A2RIPK3 | |
| SCHEMBL1032216 | 0.77 | GRM2 (0.47) | RXRANR1H2NR1H3GSTP1 | |
| SCHEMBL1031791 | 0.77 | MAPK14 (0.38) | RXRANR1H2NR1H3CYP1A2MAPK14 | |
| SCHEMBL1034139 | 0.77 | NR1H2 (0.40) | RXRANR1H2NR1H3 | |
| SCHEMBL1034850 | 0.76 | PTGS2 (0.45) | RXRANR1H2NR1H3MAPK14 | |
| SCHEMBL4904563 | 0.76 | RXRA (0.80) | RXRANR1H2NR1H3CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572660-B1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7265131-B2 | Isoquinolinone derivatives and their use as therapeutic agents | EXELIXIS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1572660-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | X-CEPTOR THERAPEUTICS INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004058717-A1 | ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132521-A1 | Isoquinolinone Derivatives and Their Use As Therapeutic Agents | NR1H2, NR1H3, NR1I2 | RXRA 25/4885NR1H2 1/4885NR1H3 2/4885 |
| US-20040204447-A1 | Isoquinolinone derivatives and their use as therapeutic agents | NR1H2, NR1I2, NR1H3 | RXRA 17/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.